Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(2):102-103; doi:10.1093/jnci/91.2.102
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sausville, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sausville, E. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 2, 102-103, January 20, 1999
© 1999 Oxford University Press

EDITORIALS

A Bcr/Abl Kinase Antagonist for Chronic Myelogenous Leukemia: a Promising Path for Progress Emerges

Edward A. Sausville

Affiliation of author: Developmental Therapeutics Program,Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.

Correspondence to: Edward A. Sausville, M.D., Ph.D., National Institutes of Health, EPN Bldg., Rm. 843, Bethesda, MD 20892-7458.

Protein kinases catalyze the transfer of the {gamma}-phosphate of adenosine triphosphate (ATP) to protein acceptors. Over the past 40 years, we have learned that protein phosphorylation is a central regulatory strategy to alter cellular function. Proteins can be phosphorylated on serine, threonine, tyrosine, and rarely histidine residues. However, tyrosine kinases have come to be understood as critical regulators of cell proliferation, invasion, metastasis, and cell survival. Tyrosine kinases exist as two major classes. In receptor tyrosine kinases, including platelet-derived growth factor receptor, epidermal growth factor receptor, and its homologue the c-erbB2 oncogene product, the kinase activity is actually part of the receptor, which has one extracellular domain to bind molecules promoting proliferation at the cell surface, a second domain that traverses the cell membrane, and an intracellular catalytic domain that acts to cause tyrosine . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. Albanell, F. Rojo, S. Averbuch, A. Feyereislova, J. M. Mascaro, R. Herbst, P. LoRusso, D. Rischin, S. Sauleda, J. Gee, et al.
Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
J. Clin. Oncol., January 1, 2002; 20(1): 110 - 124.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. W. Krystal, S. Honsawek, J. Litz, and E. Buchdunger
The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth
Clin. Cancer Res., August 1, 2000; 6(8): 3319 - 3326.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
C. Bertazzoli, E. Marchesi, L. Passoni, R. Barni, F. Ravagnani, C. Lombardo, G. M. Corneo, P. Pioltelli, E. Pogliani, and C. Gambacorti-Passerini
Differential Recognition of a BCR/ABL Peptide by Lymphocytes from Normal Donors and Chronic Myeloid Leukemia Patients
Clin. Cancer Res., May 1, 2000; 6(5): 1931 - 1935.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. le Coutre, E. Tassi, M. Varella-Garcia, R. Barni, L. Mologni, G. Cabrita, E. Marchesi, R. Supino, and C. Gambacorti-Passerini
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
Blood, March 1, 2000; 95(5): 1758 - 1766.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. A. Svingen, A. Tefferi, T. J. Kottke, G. Kaur, V. L. Narayanan, E. A. Sausville, and S. H. Kaufmann
Effects of the bcr/abl Kinase Inhibitors AG957 and NSC 680410 on Chronic Myelogenous Leukemia Cells in Vitro
Clin. Cancer Res., January 1, 2000; 6(1): 237 - 249.
[Abstract] [Full Text]